Harrow stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 64 to 79.
Can You Really Time The Stock Market?
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks compares to other publicly traded companies.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 as they launch their biggest runs. See if Harrow stock can continue to rebound and clear that threshold.
Is Harrow Stock A Buy?
Harrow stock recently reclaimed its 200-day moving average after posting positive Q2 earnings results. The biotech stock is currently not in a buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The eyecare biopharmaceutical company posted 0% earnings growth last quarter, while sales growth came in at 30%.
Harrow stock earns the No. 119 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
